Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Drug library screen to identify compounds that decrease secreted Abeta from a human cell line.

Enakshi Chakrabarti1, Jonathan D Smith

  • 1Department of Molecular Medicine, Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, Cleveland, OH 44195, USA.

Current Alzheimer Research
|June 25, 2005
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

High-density lipoprotein cholesterol influences the outcomes of lung transplantation in females, but not males.

Respiratory medicine·2026
Same author

Colocalization of eQTLs With Type 2 Diabetes and Glycemic Traits Using Whole-Genome Sequences in Diverse Populations From the NHLBI Trans-Omics in Precision Medicine (TOPMed) Program.

Diabetes·2026
Same author

Assessing capacity at an academic medical center: Epidemiology, predictors of outcomes, and the role of surrogate decision makers.

General hospital psychiatry·2026
Same author

Spatial transcriptomics in the human left atrial appendage and pulmonary vein sleeve.

Cardiovascular pathology : the official journal of the Society for Cardiovascular Pathology·2025
Same author

Zbp1 promotes atherosclerosis and lesion necrosis in mice.

Atherosclerosis·2025
Same author

Macrophage-Kruppel-Like Transcription Factor 6 Signaling Promotes Experimental Atherogenesis.

The American journal of pathology·2025
Same journal

The Role of Digital Health Technologies in Early Detection and Management of Alzheimer's Disease.

Current Alzheimer research·2026
Same journal

Quantifying Short-Term Functional Changes After Lecanemab Treatment in Early Alzheimer's Disease: An Exploratory 3-Month Follow-Up Case Report Using Eye Movement and Gait Analysis.

Current Alzheimer research·2026
Same journal

Corrigendum to: Advancing Alzheimer's Disease Diagnosis Using VGG19 and XGBoost: A Neuroimaging-Based Method.

Current Alzheimer research·2026
Same journal

Corrigendum to: Lithium Chloride Improves Electrophysiological and Memory Deficits in Rats with Streptozotocin-Induced Alzheimer's Disease.

Current Alzheimer research·2026
Same journal

Apolipoprotein E Mimetics in Targeted Drug Delivery: Advances and Therapeutic Potential for Neurodegenerative and Cardiovascular Diseases.

Current Alzheimer research·2026
Same journal

Association of Polymorphisms in Genes Involved in Serotonergic Signaling with the Risk of Developing Alzheimer's Disease.

Current Alzheimer research·2026
See all related articles

Researchers screened 2160 compounds to find potential Alzheimer disease preventatives. Three lead compounds significantly reduced amyloid beta peptide (Abeta) accumulation, showing promise for further drug development.

Area of Science:

  • Neuroscience
  • Pharmacology
  • Drug Discovery

Background:

  • Alzheimer disease is characterized by amyloid beta peptide (Abeta) accumulation.
  • Identifying therapeutic compounds to reduce Abeta is crucial for disease prevention.

Purpose of the Study:

  • To screen a drug library for compounds that decrease Abeta accumulation.
  • To identify lead compounds for further pre-clinical Alzheimer disease research.

Main Methods:

  • A primary screen of 2160 compounds was conducted on a human CNS-derived cell line.
  • Secondary and tertiary screens confirmed compound efficacy at specific dosages (5 microM and 25 microM).
  • Effects on secreted Abeta40, Abeta42, and sAPPalpha were analyzed.

Main Results:

Related Experiment Videos

  • 16 compounds (0.74%) initially reduced Abeta accumulation by at least 40%.
  • Seven compounds were confirmed effective in a secondary screen.
  • Three lead compounds demonstrated significant reductions (68-85%) in total Abeta at 25 microM.

Conclusions:

  • Lead compounds effective in reducing Abeta levels were identified.
  • These compounds warrant further investigation for their mechanism of action.
  • The identified compounds show potential for pre-clinical Alzheimer disease studies.